Cargando…

Systemically Administered Homing Peptide Targets Dystrophic Lesions and Delivers Transforming Growth Factor-β (TGFβ) Inhibitor to Attenuate Murine Muscular Dystrophy Pathology

Muscular dystrophy is a progressively worsening and lethal disease, where accumulation of functionality-impairing fibrosis plays a key pathogenic role. Transforming growth factor-β1 (TGFβ1) is a central signaling molecule in the development of fibrosis in muscular dystrophic humans and mice. Inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iqbal, Aqsa, May, Ulrike, Prince, Stuart N., Järvinen, Tero A.H., Heydemann, Ahlke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471674/ https://www.ncbi.nlm.nih.gov/pubmed/34575582 http://dx.doi.org/10.3390/pharmaceutics13091506

Ejemplares similares

Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy—Implications for Therapies
por: Heydemann, Ahlke
Publicado: (2018)

A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies
por: Heydemann, Ahlke, et al.
Publicado: (2023)

The superhealing MRL background improves muscular dystrophy
por: Heydemann, Ahlke, et al.
Publicado: (2012)

Biochemical and Functional Comparisons of mdx and Sgcg (−/−) Muscular Dystrophy Mouse Models
por: Roberts, Nathan W., et al.
Publicado: (2015)

Systemically Administered, Target Organ-Specific Therapies for Regenerative Medicine
por: Järvinen, Tero A. H., et al.
Publicado: (2015)

Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2018)

Dystrophic muscle distribution in late-stage muscular dystrophy
por: Pilato, Celeste Michelle, et al.
Publicado: (2020)

Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy
por: Siemionow, Maria, et al.
Publicado: (2021)

Enhanced Expression of the α7β1 Integrin Reduces Muscular Dystrophy and Restores Viability in Dystrophic Mice
por: Burkin, Dean J., et al.
Publicado: (2001)

Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ
por: Lamar, Kay-Marie, et al.
Publicado: (2016)

Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in mdx mouse model of Duchenne muscular dystrophy
por: Malik, Mohammad, et al.
Publicado: (2021)

Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model
por: Siemionow, Maria, et al.
Publicado: (2022)

Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2022)

Correction: Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2022)

An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus
por: Heydemann, Ahlke
Publicado: (2016)

Expression levels of TGF-β1 and CTGF are associated with the severity of Duchenne muscular dystrophy
por: Song, Yanmin, et al.
Publicado: (2017)

Heterogenetic parabiosis between healthy and dystrophic mice improve the histopathology in muscular dystrophy
por: Lu, Aiping, et al.
Publicado: (2020)

Macroglossia and less advanced dystrophic change in the tongue muscle of the Duchenne muscular dystrophy rat
por: Yamanouchi, Keitaro, et al.
Publicado: (2022)

Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration
por: Siemionow, Maria, et al.
Publicado: (2023)

Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
por: Heydemann, Ahlke, et al.
Publicado: (2023)

TGFβ-signaling in Squamous Cell Carcinoma Occurring in Recessive Dystrophic Epidermolysis Bullosa
por: Knaup, Julia, et al.
Publicado: (2011)

Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan
por: Kuraoka, Mutsuki, et al.
Publicado: (2021)

Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy
por: Alves, Francesca M., et al.
Publicado: (2022)

Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration
por: Niezgoda, Adam, et al.
Publicado: (2023)

Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy
por: Betts, Corinne A., et al.
Publicado: (2015)

Systemically Administered, Target-Specific, Multi-Functional Therapeutic Recombinant Proteins in Regenerative Medicine
por: Järvinen, Tero A.H., et al.
Publicado: (2020)

Elevated TGF β2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes
por: Bernasconi, Pia, et al.
Publicado: (2018)

Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy
por: Demonbreun, Alexis R., et al.
Publicado: (2021)

Muscle Pathology in Dystrophic Rats and Zebrafish Is Unresponsive to Taurine Treatment, Compared to the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Terrill, Jessica R., et al.
Publicado: (2023)

Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in the dystrophic muscle in Duchenne muscular dystrophy
por: Vu Hong, Ai, et al.
Publicado: (2022)

Activation of the wnt/β-Catenin Signaling Pathway in Polymyositis, Dermatomyositis and Duchenne Muscular Dystrophy
por: Liu, Fuchen, et al.
Publicado: (2016)

Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Siemionow, Maria, et al.
Publicado: (2019)

Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals?
por: Gorji, Abdolvahab Ebrahimpour, et al.
Publicado: (2023)

An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment
por: DePeaux, Kristin, et al.
Publicado: (2023)

Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
por: Siemionow, M., et al.
Publicado: (2018)

A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy
por: Hakim, Chady H., et al.
Publicado: (2017)

Dead muscle tissue promotes dystrophic calcification by lowering circulating TGF-β1 level: implications for post-traumatic heterotopic ossification
por: Li, La, et al.
Publicado: (2020)

Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei
por: Saarinen, Lilli, et al.
Publicado: (2017)

Acute conversion of patient-derived Duchenne muscular dystrophy iPSC into myotubes reveals constitutive and inducible over-activation of TGFβ-dependent pro-fibrotic signaling
por: Caputo, Luca, et al.
Publicado: (2020)

Saying NO to muscular dystrophy
por: Dove, Alan W.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_0fnpn3al0na7teo8jr4mpmtbsl